BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

...million shares in a follow-on. Extended follow-up data from the “At-Risk” TN-10 study showed that teplizumab...
...from Diabetes Consortia ”). Targets IL-1 - Interleukin-1 Pol II - RNA polymerase II BioCentury Staff teplizumab (MGA031...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...Inc. (NASDAQ:PRVB) said it paused the Phase III PROTECT study of Type I diabetes therapy teplizumab...
...group W member 1 Elizabeth S. Eaton, Staff Writer Takecab (Brand), TAK-438 (Compound #), vonoprazan fumarate (Generic) teplizumab (MGA031...
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

...interception company Provention Bio Inc. (NASDAQ:PRVB) paused randomization in the Phase III PROTECT study of teplizumab...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...NASDAQ:PRVB) said it has paused the Phase III PROTECT study of Type I diabetes therapy teplizumab...
...Staff Writer Empliciti, elotuzumab (HuLuc63, BMS-901608, PDL 063) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) Xerava, eravacycline (TP-434, IV TP-434) teplizumab (MGA031...
BioCentury | Aug 5, 2019
Company News

Aug. 5 Company Quick Takes: Briefing docs for Descovy cast doubt on full PrEP approval; plus Alnylam, Provention and more

...prevention candidate gets breakthrough Provention Bio Inc. (NASDAQ:PRVB) said FDA granted breakthrough therapy designation to teplizumab...
...Aminolevulinate synthase-1 Elizabeth S. Eaton, Staff Writer Descovy (Brand), emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) givosiran (ALN-AS1) teplizumab (MGA031...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...in the New England Journal of Medicine data which showed a single 14-day course of teplizumab...
BioCentury | Jun 13, 2019
Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

...$9.44 (217%) to $13.79 on the back of positive Phase II data for anti-CD3 mAb teplizumab...
...down $0.64 to $11.21 Thursday (see “Provention Could Use Data from Diabetes Consortia to Bring Teplizumab...
BioCentury | Jun 11, 2019
Clinical News

Provention could use data from diabetes consortia to bring teplizumab to market faster

...Results from a Phase II study showing Provention’s anti-CD3 mAb teplizumab delayed the onset of Type...
...diseases early in the course of their progression (see “Interception Springboard” ). The biotech licensed teplizumab...
...triggered a concurrent $20 million private placement from partner Amgen Inc. (NASDAQ:AMGN). Allison Johnson, Staff Writer teplizumab (MGA031...
BioCentury | Jul 20, 2018
Financial News

Provention raises $64M IPO

...pair of deals with MacroGenics Inc. (NASDAQ:MGRX) in which Provention acquired Type I diabetes treatment teplizumab...
BioCentury | Jul 20, 2018
Financial News

Provention raises $64M IPO

...pair of deals with MacroGenics Inc. (NASDAQ:MGRX) in which Provention acquired Type I diabetes treatment teplizumab...
Items per page:
1 - 10 of 45